US2020330435A1PendingUtilityA1

Medicaments for the treatment or prevention of fibrotic diseases

Assignee: BOEHRINGER INGELHEIM INTPriority: Dec 24, 2004Filed: Jul 6, 2020Published: Oct 22, 2020

Est. expiryDec 24, 2024(expired)· nominal 20-yr term from priority

Inventors:John Park Gerald Juergen Roth Armin Heckel Nveed Chaudhary Trixi Brandl Georg Dahmann Matthias Grauert

C07D 471/04A61P 43/00A61K 31/4045A61K 31/404A61K 31/445A61K 31/454A61K 9/0019A61K 31/496A61K 9/10A61K 9/0095A61K 47/38C07D 403/12A61K 9/1623A61K 31/44A61K 9/0031A61K 9/0075A61K 45/06A61K 31/4178A61K 9/0078A61K 9/02A61K 31/551C07D 209/34A61K 9/08A61K 31/495C07D 401/12A61K 31/5377C07D 295/155C07D 295/215A61K 9/2866A61K 9/2018A61K 47/10

PatentIndex Score

Cited by

References

Claims

Abstract

The present invention relates to the use of indolinones of general formula substituted in the 6 position, wherein R 1 to R 5 and X are defined as in claim 1 , the isomers and the salts thereof, particularly the physiologically acceptable salts thereof, as a medicament for the prevention or treatment of specific fibrotic diseases.

Claims

exact text as granted — not AI-modified

1 - 4 . (canceled) 
     
     
         5 . A method for treating idiopathic pulmonary fibrosis, comprising administering to a patient in need thereof a therapeutically effective amount of 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenylmethylene]-6-methoxycarbonyl-2-indolinone, or a salt thereof. 
     
     
         6 . The method of  claim 5 , wherein 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenylmethylene]-6-methoxycarbonyl-2-indolinone is in the form of a monoethanesulfonate salt.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.